Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer

被引:17
作者
Kim, Se Ik [2 ]
Song, Minsun [3 ]
Hwangbo, Suhyun [1 ]
Lee, Sungyoung [4 ]
Cho, Untack [5 ,6 ]
Kim, Ju-Hyun [7 ]
Lee, Maria [2 ]
Kim, Hee Seung [2 ]
Chung, Hyun Hoon [2 ]
Suh, Dae-Shik [7 ]
Park, Taesung [1 ]
Song, Yong-Sang [2 ]
机构
[1] Seoul Natl Univ, Dept Stat, 1 Gwanak Ro, Seoul 08826, South Korea
[2] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea
[3] Sookmyung Womens Univ, Dept Stat, Res Inst Nat Sci, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Ctr Precis Med, Seoul, South Korea
[5] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Interdisciplinary Program Canc Biol, Seoul, South Korea
[7] Univ Ulsan, Asan Med Ctr, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2019年 / 51卷 / 03期
关键词
Ovarian neoplasms; Ovarian epithelial cancer; Nomograms; Prognosis; Treatment response; Survival outcomes; PROGRESSION-FREE SURVIVAL; PRIMARY PERITONEAL; PRIMARY SURGERY; FALLOPIAN-TUBE; ADVANCED-STAGE; DOUBLE-BLIND; OPEN-LABEL; RECURRENT; BEVACIZUMAB; CHEMOTHERAPY;
D O I
10.4143/crt.2018.508
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC. Materials and Methods We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients' clinicopathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied. Results The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively. Conclusion We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.
引用
收藏
页码:1144 / 1155
页数:12
相关论文
共 27 条
[1]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[2]   Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer [J].
Barlin, Joyce N. ;
Yu, Changhong ;
Hill, Emily K. ;
Zivanovic, Oliver ;
Kolev, Valentin ;
Levine, Douglas A. ;
Sonoda, Yukio ;
Abu-Rustum, Nadeem R. ;
Huh, Jae ;
Barakat, Richard R. ;
Kattan, Michael W. ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2012, 125 (01) :25-30
[3]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[4]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[5]   Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma [J].
Chi, Dennis S. ;
Palayekar, Meena J. ;
Sonoda, Yukio ;
Abu-RuStum, Nadeern R. ;
Awtrey, Christopher S. ;
Huh, Jae ;
Eisenhauer, Eric L. ;
Barakat, Richard R. ;
Kattan, Michael W. .
GYNECOLOGIC ONCOLOGY, 2008, 108 (01) :191-194
[6]   Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach [J].
Chi, DS ;
Franklin, CC ;
Levine, DA ;
Akselrod, F ;
Sabbatini, P ;
Jarnagin, WR ;
DeMatteo, R ;
Poynor, EA ;
Abu-Rustum, NR ;
Barakat, RR .
GYNECOLOGIC ONCOLOGY, 2004, 94 (03) :650-654
[7]   Ovarian Cancer [J].
Cho, Kathleen R. ;
Shih, Ie-Ming .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 :287-313
[8]   Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial [J].
Coleman, Robert L. ;
Brady, Mark F. ;
Herzog, Thomas J. ;
Sabbatini, Paul ;
Armstrong, Deborah K. ;
Walker, Joan L. ;
Kim, Byoung-Gie ;
Fujiwara, Keiichi ;
Tewari, Krishnansu S. ;
O'Malley, David M. ;
Davidson, Susan A. ;
Rubin, Stephen C. ;
DiSilvestro, Paul ;
Basen-Engquist, Karen ;
Huang, Helen ;
Chan, John K. ;
Spirtos, Nick M. ;
Ashfaq, Raheela ;
Mannel, Robert S. .
LANCET ONCOLOGY, 2017, 18 (06) :779-791
[9]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[10]   The Global Burden of Cancer 2013 Global Burden of Disease Cancer Collaboration [J].
Fitzmaurice, Christina ;
Dicker, Daniel ;
Pain, Amanda ;
Hamavid, Hannah ;
Moradi-Lakeh, Maziar ;
Maclntyre, Michael F. ;
Allen, Christine ;
Hansen, Gillian ;
Woodbrook, Rachel ;
Wolfe, Charles ;
Hamadeh, Randah R. ;
Moore, Ami ;
Werdecker, Andrea ;
Gessner, Bradford D. ;
Te Ao, Braden ;
McMahon, Brian ;
Karimkhani, Chante ;
Yu, Chuanhua ;
Cooke, Graham S. ;
Schwebel, David C. ;
Carpenter, David O. ;
Pereira, David M. ;
Nash, Denis ;
Kazi, Dhruv S. ;
De Leo, Diego ;
Plass, Dietrich ;
Ukwaja, Kingsley N. ;
Thurston, George D. ;
Jin, Kim Yun ;
Simard, Edgar P. ;
Mills, Edward ;
Park, Eun-Kee ;
Catala-Lopez, Ferran ;
DeVeber, Gabrielle ;
Gotay, Carolyn ;
Khan, Gulfaraz ;
Hosgood, H. Dean, III ;
Santos, Itamar S. ;
Leasher, Janet L. ;
Singh, Jasvinder ;
Leigh, James ;
Jonas, Jost B. ;
Sanabria, Juan ;
Beardsley, Justin ;
Jacobsen, Kathryn H. ;
Takahashi, Ken ;
Franklin, Richard C. ;
Ronfani, Luca ;
Montico, Marcella ;
Naldi, Luigi .
JAMA ONCOLOGY, 2015, 1 (04) :505-527